Release Date: August 15, 2025
Expiration Date: August 15, 2026
Activity Overview
TROP2 is an actionable target in the treatment of triple-negative breast cancer (TNBC) owing to its high expression on tumor cells and low expression on healthy tissue. TROP2-targeting antibody-drug conjugates (ADCs) deliver potent cytotoxic chemotherapy to cancer cells. In this activity, two experts in TNBC management dissect clinical trial and real-world data for ADCs used to treat TNBC.
Target Audience
This activity is directed toward medical oncologists, APPs, nurses, pharmacists, and other HCPs who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Develop evidence-based strategies for integrating ADCs in the management of patients with metastatic TNBC
Filipa Lynce, MD
Assistant Professor of Medicine
Harvard Medical School
Director, Inflammatory Breast Center
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Adviser: AstraZeneca, Daiichi Sankyo, Eli Lilly, Pfizer; Grant/Research Funding: AstraZeneca, Gilead Sciences, Ideaya Biosciences, Incyte, Merck, Zentalis Pharmaceuticals; Executive Role: Alliance Foundation Trials
Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
University of Chicago Medicine
Chicago, IL
Disclosures: Advisory Board: Arvinas, AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, GE, Gilead Sciences, Guardant Health, Merck, Moderna, Novartis, OBI Pharma, Pfizer, Sanofi, Seagen, Stemline Therapeutics, Summit Therapeutics; Research Funding: Arvinas, AstraZeneca, Bristol Myers Squibb, Corcept Therapeutics, Genentech/Roche, Gilead Sciences, GSK, Merck, Novartis, OBI Pharma, Pfizer, Relay Therapeutics, Seagen, Sun Pharma, Taiho Oncology
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here